Los Angeles Capital Management LLC Immunovant, Inc. Transaction History

Los Angeles Capital Management LLC

  • $24.7 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024
SELL
$25.1 - $31.61 $109,059 - $137,345
-4,345 Reduced 30.23%
10,026 $264,000
Q1 2024

Apr 05, 2024
BUY
$30.27 - $43.79 $282,570 - $408,779
9,335 Added 185.37%
14,371 $464,000
Q4 2023

Feb 06, 2024
BUY
$31.31 - $44.19 $157,677 - $222,540
5,036 New
5,036 $212,000
Q2 2021

Aug 05, 2021
SELL
$9.4 - $16.85 $130,472 - $233,878
-13,880 Closed
0 $0
Q1 2021

May 05, 2021
BUY
$13.08 - $49.6 $181,550 - $688,448
13,880 New
13,880 $222,000

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email